Details of the Drug Combination

General Information of Drug Combination (ID: DCOTXWB)

Drug Combination Name
Clascoterone Sivelestat
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Clascoterone   DMPGR1E Sivelestat   DM6BZCV
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 6.69
Bliss Independence Score: 6.69
Loewe Additivity Score: 20.56
LHighest Single Agent (HSA) Score: 20.56

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Clascoterone
Disease Entry ICD 11 Status REF
Acne vulgaris ED80 Approved [2]
Clascoterone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Androgen receptor (AR) TTS64P2 ANDR_HUMAN Antagonist [2]
------------------------------------------------------------------------------------
Indication(s) of Sivelestat
Disease Entry ICD 11 Status REF
Crohn disease DD70 Phase 3 [3]
Multiple sclerosis 8A40 Phase 3 [3]
Psoriatic arthritis FA21 Phase 3 [3]
Pyoderma gangrenosum EB21 Phase 3 [4]
Rheumatoid arthritis FA20 Phase 3 [3]
Ulcerative colitis DD71 Phase 3 [3]
Anterior uveitis 9A96 Application submitted [5]
Axial spondyloarthritis FA92.0 Application submitted [3]
Sivelestat Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Pancreatic elastase 1 (CELA1) TT3NKIB CELA1_HUMAN Inhibitor [6]
Neutrophil elastase (NE) TTPLTSQ ELNE_HUMAN Inhibitor [7]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome... Shock. 2010 Jan;33(1):14-8.
7 Neutrophil elastase inhibitor (sivelestat) reduces the levels of inflammatory mediators by inhibiting NF-kB. Inflamm Res. 2009 Apr;58(4):198-203.